Vanguard Group Inc Chroma Dex Corp. Transaction History

Vanguard Group Inc

$5.12 Trillion
Q2 2024

A detailed history of Vanguard Group Inc transactions in Chroma Dex Corp. stock. As of the latest transaction made, Vanguard Group Inc holds 3,386,425 shares of CDXC stock, worth $19.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,386,425

Previous 3,048,119 11.1%

Holding current value

$19.8 Million

Previous $10.6 Million 12.85%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$2.44 - $4.32 $825,466 - $1.46 Million	338,306 Added 11.1%	3,386,425 $9.24 Million
Q4 2023 Feb 14, 2024	BUY	$1.28 - $1.6 $5,730 - $7,163	4,477 Added 0.15%	3,048,119 $4.36 Million
Q2 2023 Aug 14, 2023	SELL	$1.31 - $1.79 $110,532 - $151,033	-84,376 Reduced 2.7%	3,043,642 $4.78 Million
Q1 2023 May 15, 2023	BUY	$1.48 - $2.19 $767,858 - $1.14 Million	518,823 Added 19.88%	3,128,018 $4.79 Million
Q4 2022 Feb 10, 2023	BUY	$1.25 - $1.94 $472,372 - $733,122	377,898 Added 16.94%	2,609,195 $4.38 Million
Q3 2022 Nov 14, 2022	BUY	$1.19 - $2.06 $58,135 - $100,637	48,853 Added 2.24%	2,231,297 $2.74 Million
Q2 2022 Aug 12, 2022	SELL	$1.59 - $2.7 $952,398 - $1.62 Million	-598,993 Reduced 21.54%	2,182,444 $3.65 Million
Q1 2022 May 13, 2022	BUY	$2.02 - $3.92 $485,636 - $942,422	240,414 Added 9.46%	2,781,437 $6.84 Million
Q4 2021 Feb 14, 2022	SELL	$3.74 - $6.7 $338,657 - $606,685	-90,550 Reduced 3.44%	2,541,023 $9.5 Million
Q3 2021 Nov 12, 2021	BUY	$6.05 - $10.41 $138,762 - $238,763	22,936 Added 0.88%	2,631,573 $16.5 Million
Q2 2021 Aug 13, 2021	BUY	$6.66 - $10.92 $17.4 Million - $28.5 Million	2,608,637 New	2,608,637 $25.7 Million

Others Institutions Holding CDXC

# of Institutions

Shares Held

16.5M

Call Options Held

91.7K

Put Options Held

18.9K

View Full List

About ChromaDex Corp.

Ticker CDXC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,350,896
Market Cap $401M
Description
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingre...

More about CDXC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Chroma Dex Corp. Transaction History